Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
Provide pre-approval single-patient Expanded Access (Compassionate Use) of elranatamab for patients with relapsed/refractory multiple myeloma
Full description
In Expanded Access, treating physicians are the Sponsors
Expanded Access requests from treating physicians should be directed to www.pfizercares.com Availability will depend on location.
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Must have relapsed/refractory multiple myeloma (RRMM) and be refractory to at least one immunomodulatory drug, one proteasome inhibitor and one anti-CD38 antibody. Must have evidence of disease progression after last therapy. Must have exhausted all available treatment options accessible as local standard of care and not be eligible for participation in any ongoing clinical trial. Additional eligibility criteria may be required.
Loading...
Central trial contact
PfizerCares
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal